Skip to main content
Premium Trial:

Request an Annual Quote

GenePOC Receives CE Mark for Drug-Resistant Bacteria Test

NEW YORK (GenomeWeb) – GenePOC announced today the CE marking of its Carba assay for carbapenemase-producing organisms, a class of bacteria resistant to carbapenem antibiotics.

The PCR-based in vitro diagnostic is designed for the detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48-like, and blaIMP gene sequences, which are associated with carbapenem resistance. It can provide results for up to eight sample in approximately 70 minutes and runs on the Canadian firm's Revogene automated instrument.

"A test [that] offers rapid and accurate results will contribute to the identification of colonized patients, therefore limit the spread of these organisms in healthcare settings and save on hospital costs," GenePOC CEO Patrice Allibert said in a statement. "Our GenePOC Carba assay also demonstrates the power of our technology to be compatible with panel detection."

Earlier this year, GenePOC received US Food and Drug Administration clearance for its group A Streptococcus test. The Revogene system won FDA clearance in mid-2017.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.